For the Inventor, By the Inventor

Enter assignee name

Fujirebio Inc.

USPTO Granted Patents = 102

% Expired Patents = 21.6

CIPO Patents = 1

EPO Patents = 31

Trademarks = 11

Forward Citations = 725

Loading Chart...

Loading Chart...

165 inventors (with patents filed for the assignee):

Hiroshi Ikawa (22 out of 26 patents)

Tetsuaki Yamaura (13 out of 15 patents)

Yoshihiro Ashihara (12 out of 27 patents)

4. Masakatsu Matsumoto (9 out of 14 patents)

5. Katsumi Aoyagi (8 out of 14 patents)

6. Yoshiaki Uchida (8 out of 9 patents)

7. Masahisa Okada (8 out of 11 patents)

8. Nobuko Watanabe (8 out of 9 patents)

9. Shintaro Yagi (6 out of 17 patents)

10. Masami Sugiyama (6 out of 11 patents)

11. Yoshihiro Kurano (6 out of 6 patents)

12. Yasuko Konagai (6 out of 6 patents)

13. Akiyoshi Kadoiri (6 out of 7 patents)

14. Eiko Mori (6 out of 16 patents)

15. Hisako Kobayashi (6 out of 6 patents)

Core Competencies:

Immunoassay

Cardiac Troponin

Hepatitis B Assay

Vitamin D Measurement

PIVKA-II Assay

Antibody

Troponin

Prostaglandin E

Nucleic Acid

Chemiluminescence

Diagnostics

Reagents

102 patents: Sort by Forward Citations

1. 12196768 - Method of testing a blood for macrolide immunosuppressant (2025-01-14),

2. 12038440 - Lectin-binding substance measurement method, lectin-binding substance measurement kit, and capture carrier for use in these (2024-07-16),

3. 11988666 - Lectin-binding substance measurement method, lectin-binding substance measurement kit, and blocked labeled lectin for use in these (2024-05-21),

4. 11802867 - Cardiac troponin assay method and assay reagent (2023-10-31),

5. 11768209 - Method and reagent for measuring thyroglobulin (2023-09-26),

6. 11604199 - Treatment liquid for exclusion of steroid included in cyclodextrin (2023-03-14),

7. 11454632 - Assay method and assay kit for hepatitis B virus S antigen (2022-09-27),

8. 11169162 - Kit and method for measuring prostaglandin E-major urinary metabolite (2021-11-09),

9. 10830771 - PIVKA-II assay method and method for manufacturing reagent or kit for PIVKA-II immunoassay (2020-11-10),

10. 10634676 - Method and kit for simultaneously detecting human parvovirus B19 antigen and antibody (2020-04-28),

11. 10571479 - Vitamin D measurement method and measurement kit (2020-02-25),

12. 10562039 - Automatic analysis device and separation and washing method (2020-02-18),

13. 10539559 - PIVKA-II measurement method, measurement reagent, and measurement kit (2020-01-21),

14. 10527638 - Automated analyzer and nozzle-cleaning method (2020-01-07),

15. 10138508 - Method for measuring modified nucleobase using guide probe, and kit therefor (2018-11-27),

Company Overview

Fujirebio Inc., headquartered in Tokyo, specializes in the development and manufacturing of advanced immunoassay techniques. The company focuses on critical diagnostic areas, including cardiac troponin testing, hepatitis B assays, and vitamin D measurement. With a commitment to innovation, Fujirebio leverages its expertise in antibody technology to enhance diagnostic accuracy and patient care. The organization plays a significant role in the global healthcare landscape, providing essential tools for disease detection and management.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

102 Patents

#534 in Tokyo

#1,109 in Japan

#7,654 in the World

Fujirebio Inc.

Forward Citations = 725

165 inventors:

Hiroshi Ikawa (22 out of 26 patents)

Tetsuaki Yamaura (13 out of 15 patents)

Yoshihiro Ashihara (12 out of 27 patents)

4. Masakatsu Matsumoto (9 out of 14 patents)

5. Katsumi Aoyagi (8 out of 14 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Fujirebio Inc.. Retrieved from https://idiyas.com/company/fujirebio

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…